Evaluation of comorbid diseases in obstructive sleep apnea syndrome

SUMMARY OBJECTIVE: It is known that obstructive sleep apnea syndrome affects many systems due to hypoxemia and hypercarbia. We aimed to demonstrate with the utilization of well-standardized questionnaire tools and electrophysiological tests that cognitive impairment, depression, autonomic dysfunction, and metabolic syndrome may occur in association with obstructive sleep apnea syndrome. METHODS: The electrophysiological examination protocol of autonomic nervous system functions was performed with sympathetic skin response and R-R Interval. Patients were administered Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Montreal Cognitive Assessment, and Hamilton Depression Rating Scale by physicians in face-to-face interviews. RESULTS: This study included 148 participants, consisting of 73 patients and 75 controls. There was a statistically significant difference between the patient group and control group with regard to sympathetic skin response, R-R Interval, post-hyperventilation R-R Interval, and R-R Interval variation (p<0.001). A statistically significant difference was observed between the patient group and control group in terms of median Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and Montreal Cognitive Assessment scores. It was observed that the control group achieved significantly better scores than the patient group in delayed recall (p<0.001) and language (p<0.05) categories. CONCLUSION: Obstructive sleep apnea syndrome patients should be screened for diseases, especially in the cardiovascular system, that cause serious morbidity and impair functionality such as dementia and depression. We believe that many comorbid diseases encountered in obstructive sleep apnea syndrome patients can be prevented with early diagnosis and continuous positive airway pressure treatment.

Evaluation of comorbid diseases in obstructive sleep apnea syndrome.

OBJECTIVE: It is known that obstructive sleep apnea syndrome affects many systems due to hypoxemia and hypercarbia. We aimed to demonstrate with the utilization of well-standardized questionnaire tools and electrophysiological tests that cognitive impairment, depression, autonomic dysfunction, and metabolic syndrome may occur in association with obstructive sleep apnea syndrome. METHODS: The electrophysiological examination protocol of autonomic nervous system functions was performed with sympathetic skin response and R-R Interval. Patients were administered Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Montreal Cognitive Assessment, and Hamilton Depression Rating Scale by physicians in face-to-face interviews. RESULTS: This study included 148 participants, consisting of 73 patients and 75 controls. There was a statistically significant difference between the patient group and control group with regard to sympathetic skin response, R-R Interval, post-hyperventilation R-R Interval, and R-R Interval variation (p<0.001). A statistically significant difference was observed between the patient group and control group in terms of median Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and Montreal Cognitive Assessment scores. It was observed that the control group achieved significantly better scores than the patient group in delayed recall (p<0.001) and language (p<0.05) categories. CONCLUSION: Obstructive sleep apnea syndrome patients should be screened for diseases, especially in the cardiovascular system, that cause serious morbidity and impair functionality such as dementia and depression. We believe that many comorbid diseases encountered in obstructive sleep apnea syndrome patients can be prevented with early diagnosis and continuous positive airway pressure treatment.

Impaired Visual Habituation in Idiopathic Generalized Epilepsy with Photosensitivity Patients.

INTRODUCTION: In this study, our goal was to analyze further the cortical excitability levels in idiopathic generalized epilepsy (IGE) patients with and without photosensitivity. METHODS: Forty-two patients (16 men and 26 women; mean age 30±8 years; range: 18-43 years) with IGE and thirty healthy age-matched control subjects (15 men and 15 women; mean age 35±3 years; range: 20-45 years) were enrolled for the investigation. We investigated the following two groups: 18 subjects with IGE with photosensitivity (IGE+PS), and 24 patients with IGE without photosensitivity (IGE-PS). Pattern reversal and potential inter-peak amplitudes, N75-P100 and P100-N145, as well as the corresponding latencies (N75, P100, and N145) for one hundred responses were measured 6 times. A linear regression slope was used for N75-P100 and P100-N145. RESULTS: Statistical analysis showed difference between groups where the IGE+PS had reduced N75-P100 compared to IGE-PS and controls. In IGE+PS group, the amplitude of N75-P100 was drastically reduced receiving antiepileptic therapy compared to those not receiving any anti-epileptic treatment (p=0.035). CONCLUSION: These results show that the IGE+PS group has a different photoparoxysmal response phenotype driven by an unknown and distinct molecular mechanism. Pre-activation cortical excitability may be increased in IGE+PS patients compared to the IGE-PS or in healthy group. PR-VEP habituation may project the pathophysiological mechanisms underlying photosensitivity and it may be potential biomarker in patients with IGE+PS.

Pharmacoresistant seizures in neurofibromatosis type 1 related to hippocampal sclerosis: Three case presentation and review.

Neurofibromatosis type 1 (NF1) is an autosomal dominantly inherited disorder, with an estimated prevalence of 1 in 3000-4000 people. Seizures occur 4-7% of individuals with NF1, mostly due to associated brain tumors or cortical malformations. Hippocampal sclerosis (HS) in the patients with NF1 has been reported very rarely and only 15 patients were found in review of English literature. We presented here 3 additional patients with NF1 and intractable seizures due to hippocampal sclerosis; in whom one of them underwent epilepsy surgery and he is seizure free for 5 years after right temporal lobectomy.

Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.

This case report presents a patient with tardive dyskinesia who also suffered from masticatory muscle pain and temporomandibular joint osteoarthrosis. The patient was treated with clozapine in gradually increasing doses and two injections of botulinum toxin type A one year apart. Involuntary movements of mandibular clenching and bruxing disappeared and pain was relieved to a great extent. Reappearances of dyskinetic movements and pain were observed during the follow-up period of 1.5 years.